104 Consolidated income statement for the year ended 31st December 2010 2010 Results BEFORE MAJORAJOR restructuring restructuring Total.
OTES m m m Turnover 6 28,392 Cost of sales 7,592 Gross profit 20,800 Selling, general and administration 13,053 Research and development 3,964 493 4,457 Other operating income 493 493 Operating profit 9 3,783 Finance income 11 116 116 Finance costs 12 3 831 Profit on disposal of interest in associates 8 3HARE OF AFTER TAX PROFITS OF ASSOCIATES AND JOINT VENTURES 13 81 Profit before taxation 3,157 4AXATION 14 240 1,304 Profit after taxation for the year 2,961 1,853 Profit attributable to non-controlling interests 219 219 Profit attributable to shareholders 2,742 1,634 2,961 1,853 Basic earnings per share pence 32.1p Diluted earnings per share pence 31.9p 4HE CALCULATION OF @2ESULTS BEFORE MAJOR RESTRUCTURING IS DESCRIBED IN.
OTE @0RESENTATION OF THE FINANCIAL STATEMENTS Consolidated statement of comprehensive income for the year ended 31st December 2010 2010 m Profit for the year 1,853 %XCHANGE MOVEMENTS ON OVERSEAS NET ASSETS AND NET INVESTMENT HEDGES 166 RecLASSIFICATION OF EXCHANGE ON LIQUIDATION OR DISPOSAL OF OVERSEAS SUBSIDIARIES 2 4AX ON EXCHANGE MOVEMENTS Fair value movements on available-for-sale investments 94 $EFERRED TAX ON fair value movements on available-for-sale investments 25 Reclassification of fair value movements on available-for-sale investments 1 $EFERRED TAX REVERSED ON REClassification of available-for-sale investments 3 Fair value movements on cash flow hedges 8 $EFERRED TAX ON FAIR VALUE MOVEMENTS ON CASH FLOW HEDGES 1 Reclassification of cash flow hedges to income statement 3 Fair value movement on subsidiary acquisition Cash flow hedge reclassified to goodwill 6 Actuarial losses on defined benefit plans 1 $EFERRED TAX ON ACTUARIAL MOVEMENTS IN DEFINED BENEFIT PLANS 1 THER COMPREHENSIVE INCOME EXPENSE FOR THE YEAR 233 Total comprehensive income for the year 2,086 Total comprehensive income for the year attributable to: Shareholders 1,847.
OTES m m Non-current assets Property, plant and equipment 17 9,045 9,374 Goodwill 3,606 3,361 Other intangible assets 19 8,532 NVESTMENTS IN ASSOCIATES AND JOINT VENTURES 20 1,081 Other investments 21 711 $EFERRED TAX ASSETS 14 2,566 2,374 Derivative financial instruments 41 97 Other non-current assets 22 556 Total non-current assets 26,194 Current assets Inventories 23 3,837 4,064 #URRENT TAX RECOVERABLE 14 56 Trade and other receivables 24 5,793 6,492 Derivative financial instruments 41 93 129, IQUID INVESTMENTS 32 184 Cash and cash equivalents 6,057 Assets held for sale 26 16 14 Total current assets 16,036 Total assets 42,230 Current liabilities Short-term borrowings 32 291 1,471 Trade and other payables 27 6,888 6,772 Derivative financial instruments 41 188 #URRENT TAX PAYABLE 14 1,047 Short-term provisions 29 4,380 Total current liabilities 12,794 Non-current liabilities, ONG TERM BORROWINGS 32 14,809 $EFERRED TAX LIABILITIES 14 707 Pensions and other post-employment benefits 2,672 Other provisions 29 904 Derivative financial instruments 41 5 Other non-current liabilities 30 594 Total non-current liabilities 19,691 20,002 Total liabilities 32,485 32,120 Net assets 9,745 10,742 Equity Share capital 33 1,418 1,416 Share premium account 33 1,428 Retained earnings 34 4,779 6,321 Other reserves 34 1,262 900 Shareholders equity 8,887.
"ON CONTROLLING INTERESTS 858 737 Total equity 9,745 10,742 !PPROVED BY THE ""OARD ON STARCH Sir Christopher Gent Chairman GSK Annual Report 2010 Financial statements P102P191 Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 107 Consolidated statement of changes in equity for the year ended 31st December 2010 3HAREHOLDERS EQUITY."
ON Share Share Retained Other controlling Total capital premium earnings reserves Total interests equity m m m m m m m !T ST ANUARY 1,266 9,603 307 9,910 profit for the year 4,602 4,602 110 4,712 THER COMPREHENSIVE INCOME EXPENSE FOR THE YEAR 121 49 117 Distributions to non-controlling interests 79 79 Dividends to shareholders 2,929 2,929 2,929 Ordinary shares issued 2 60 62 62 Ordinary shares purchased and cancelled 90 3,706 90 3,706 3,706 Ordinary shares acquired by ESOP Trusts 19 19 19 Ordinary shares transferred by ESOP Trusts 10 10 10 Write-down of shares held by ESOP Trusts Share-based incentive plans 241 241 241 4AX ON SHARE BASED INCENTIVE PLANS 1 1 1 !T ST $ECEMBER 1,326 4,622 7,931 8,318 profit for the year 5,669 THER COMPREHENSIVE EXPENSE INCOME FOR THE YEAR 663 27 636 37 673 Distributions to non-controlling interests 89 Changes in non-controlling interests 338 Put option over non-controlling interest 2 2 2 Dividends to shareholders 3,003 3,003 3,003 Ordinary shares issued 1 42 43 43 Ordinary shares acquired by ESOP Trusts 57 Ordinary shares transferred by ESOP Trusts 13 13 13 Write-down of shares held by ESOP Trusts Share-based incentive plans 171 171 171 4AX ON SHARE BASED INCENTIVE PLANS 14 14 14 At 31st December 2009 1,416 6,321 900 737 10,742 profit for the year 1,634 1,634 219 1,853 Other comprehensive income for the year 144 69 213 20 233 Distributions to non-controlling interests 118 Dividends to shareholders 3,205 Ordinary shares issued 2 60 62 62 Ordinary shares acquired by ESOP Trusts 16 16 16 Ordinary shares transferred by ESOP Trusts 17 17 17 Write-down of shares held by ESOP Trusts 292 292 Share-based incentive plans 175 4AX ON SHARE BASED INCENTIVE PLANS 2 2 2 At 31st December 2010 4,779 1,262 9,745 GSK Annual Report 2010 108 Consolidated cash ow statement for the year ended 31st December 2010 2010 2009.
OTES m m m Cash flow from operating activities 0ROFIT AFTER TAXATION FOR THE YEAR 1,853 4,712 !DJUSTMENTS RECONCILING PROFIT AFTER TAX TO OPERATING CASH FLOWS 36 6,778 4,343 Cash generated from operations 8,631 4AXATION PAID 1,834 1,704.
ET CASH INFLOW FROM OPERATING ACTIVITIES 6,797 Cash flow from investing activities Purchase of property, plant and equipment 1,014 1,437 Proceeds from sale of property, plant and equipment 92 20 Purchase of intangible assets 621 632 Proceeds from sale of intangible assets 126 171 Purchase of equity investments 279 Proceeds from sale of equity investments 27 42 Purchase of businesses, net of cash acquired 354 2,792 NVESTMENTS IN ASSOCIATES AND JOINT VENTURES 61 29 9 Decrease in liquid investments 91 Interest received 107 90 320 $IVIDENDS FROM ASSOCIATES AND JOINT VENTURES 18 17 12 Proceeds from disposal of associates.
ET CASH OUTFLOW FROM INVESTING ACTIVITIES 1,868 4,013 1,149 Cash flow from financing activities Proceeds from own shares for employee share options 17 13 9 Shares acquired by ESOP Trusts 16 19 Issue of share capital 33 62 43 62 Purchase of own shares for cancellation 3,706 Increase in long-term loans Increase in short-term loans 6 646 Repayment of short-term loans 1,296 3,334.
ET REPAYMENT OF OBLIGATIONS UNDER FINANCE LEASES 45 Interest paid 775 730 Dividends paid to shareholders 3,205 3,003 2,929 Distributions to non-controlling interests 118 79 Other financing cash flows 201 109.
ET CASH OUTFLOW FROM FINANCING ACTIVITIES 5,571 2,774 $ECREASE INCREASE IN CASH AND BANK OVERDRAFTS 37 642 %XCHANGE ADJUSTMENTS 81 1,103 #ASH AND BANK OVERDRAFTS AT BEGINNING OF YEAR 6,368 3,221 #ASH AND BANK OVERDRAFTS AT END OF YEAR 5,807 #ASH AND BANK OVERDRAFTS AT END OF YEAR COMPRISE Cash and cash equivalents 6,057 Overdrafts 250 177 5,807 GSK Annual Report 2010 Financial statements P102P191
